Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind Phase III Clinical Study Comparing the Efficacy and Safety of BAT5906 and Ranibizumab (Lucentis®) in Patients With Neovascular Age-related Macular Degeneration

NCT05439629 is registered in ClinicalTrials.gov with Bio-Thera Solutions as lead sponsor.

NCT NCT05439629
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05439629 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind Phase III Clinical Study Comparing the Efficacy and Safety of BAT5906 and Ranibizumab (Lucentis®) in Patients With Neovascular Age-related Macular Degeneration
Lead sponsor
Bio-Thera Solutions
Phase
Phase 3
Overall status
Completed
Start date
July 7, 2022
Completion date
April 22, 2025
Enrollment
488 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular (wet) age-related macular degeneration